 NOVATO, Calif., Oct. 04, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 8,620 shares of common stock of the company and 2,880 restricted stock units of the companys common stock to one newly hired non-executive officer employee of the company. The award was approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 1, 2021, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635c4. 